We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urinary RNA Assay May Replace Needle Biopsy for Detection of Kidney Transplant Rejection

By LabMedica International staff writers
Posted on 17 Mar 2014
Determination of mRNA signatures in urine samples may replace needle biopsy for diagnosing kidney dysfunction following transplant surgery.

Investigators at Weill Cornell Medical College (New York, NY, USA) measured absolute levels of 26 pre-specified mRNAs in urine samples collected from kidney graft recipients at the time of needle biopsy for acute allograft dysfunction and investigated whether differential diagnosis of acute graft dysfunction would be feasible using urinary cell mRNA profiles. They profiled 52 urine samples from 52 patients with biopsy specimens indicating acute rejection (26 acute T cell–mediated rejections and 26 acute antibody-mediated rejections) and 32 urine samples from 32 patients with acute tubular injury without acute rejection.

Results of stepwise discriminant mRNA analysis identified a linear combination of mRNAs for CD3epsilon, CD105, TLR4, CD14, complement factor B, and vimentin that distinguished acute rejection from acute tubular injury. Among patients diagnosed with acute rejection, a similar statistical approach identified a linear combination of mRNAs for CD3epsilon, CD105, CD14, CD46, and 18S rRNA that distinguished T cell–mediated rejection from antibody-mediated rejection.

“Using statistical methods we have combined the mRNAs to yield a diagnostic signature,” said senior author Dr. Thangamani Muthukumar, assistant professor of medicine at Weill Cornell Medical College. “Our study shows that when the creatinine level is elevated in the blood of a kidney transplant recipient, use of our urine test would differentiate the common causes of kidney dysfunction that led to the elevation in creatinine, hence benefiting many patients by allowing them to avoid the need for an invasive needle biopsy.”

The study showing the correspondence between mRNA signatures and needle biopsy results was published in the March 7, 2014, online edition of the Journal of the American Society of Nephrology.

Related Links:

Weill Cornell Medical College



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit

Latest Pathology News

AI-Based Model Predicts Kidney Cancer Therapy Response
17 Mar 2014  |   Pathology

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
17 Mar 2014  |   Pathology

World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
17 Mar 2014  |   Pathology